Intra-Cellular Therapies Cash on Hand 2013-2022 | ITCI
Intra-Cellular Therapies cash on hand from 2013 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Intra-Cellular Therapies cash on hand for the quarter ending March 31, 2022 was $0.773B, a 26.07% increase year-over-year.
- Intra-Cellular Therapies cash on hand for 2021 was $0.414B, a 37.2% decline from 2020.
- Intra-Cellular Therapies cash on hand for 2020 was $0.659B, a 194.12% increase from 2019.
- Intra-Cellular Therapies cash on hand for 2019 was $0.224B, a 35.54% decline from 2018.
Intra-Cellular Therapies Annual Cash on Hand
(Millions of US $) |
| 2021 |
$414 |
| 2020 |
$659 |
| 2019 |
$224 |
| 2018 |
$348 |
| 2017 |
$464 |
| 2016 |
$384 |
| 2015 |
$475 |
| 2014 |
$130 |
| 2013 |
$37 |
| 2012 |
$19 |
Intra-Cellular Therapies Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$773 |
| 2021-12-31 |
$414 |
| 2021-09-30 |
$479 |
| 2021-06-30 |
$556 |
| 2021-03-31 |
$613 |
| 2020-12-31 |
$659 |
| 2020-09-30 |
$723 |
| 2020-06-30 |
$409 |
| 2020-03-31 |
$450 |
| 2019-12-31 |
$224 |
| 2019-09-30 |
$255 |
| 2019-06-30 |
$285 |
| 2019-03-31 |
$313 |
| 2018-12-31 |
$348 |
| 2018-09-30 |
$376 |
| 2018-06-30 |
$404 |
| 2018-03-31 |
$437 |
| 2017-12-31 |
$464 |
| 2017-09-30 |
$328 |
| 2017-06-30 |
$343 |
| 2017-03-31 |
$368 |
| 2016-12-31 |
$384 |
| 2016-09-30 |
$538 |
| 2016-06-30 |
$443 |
| 2016-03-31 |
$456 |
| 2015-12-31 |
$475 |
| 2015-09-30 |
$511 |
| 2015-06-30 |
$204 |
| 2015-03-31 |
$235 |
| 2014-12-31 |
$130 |
| 2014-09-30 |
$136 |
| 2014-06-30 |
$140 |
| 2014-03-31 |
$146 |
| 2013-12-31 |
$37 |
| 2013-09-30 |
$46 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.204B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
